Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Eisai Stories

2012-12-17 12:24:04

WOODCLIFF LAKE, N.J. and ATLANTA, Dec. 17, 2012 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset purchase agreement to divest U.S. rights for Gliadel® Wafer (polifeprosan 20 with carmustine implant) to specialty pharmaceutical company Arbor Pharmaceuticals, Inc. As part of the transaction, which takes effect immediately, Eisai has transferred the New Drug Application (NDA) for Gliadel to Arbor,...

2012-12-11 08:27:39

WOODCLIFF LAKE, N.J., Dec. 11, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) determined that Eisai has met the FDA's Written Request requirements for pediatric exclusivity for ACIPHEX(® )(rabreprazole sodium). As a result, Eisai has now gained an additional 6 months of United States market exclusivity for ACIPHEX, which will expire on November 8, 2013. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The granting of...

2012-12-07 08:24:49

SAN ANTONIO, Dec. 7, 2012 /PRNewswire/ -- Results from the first large, global Phase III study of Halaven(®) (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The 1,102-patient, open-label, multi-center study compared Halaven versus capecitabine (Xeloda(®)) in women with locally advanced or metastatic...

2012-11-30 08:24:39

WOODCLIFF LAKE, N.J., Nov. 30, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex® Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age. (Logo:...

2012-11-28 12:26:49

WOODCLIFF LAKE, N.J., Nov. 28, 2012 /PRNewswire/ -- Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. The meeting will be held December 4-8, 2012 at the Henry B. Gonzalez Convention Center in San Antonio, TX. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) These studies highlight Eisai's current and ongoing clinical research efforts with Halaven(®) (eribulin...

2012-11-26 08:24:59

CAMBRIDGE, Mass., Nov. 26, 2012 /PRNewswire/ -- Following a productive first year of headcount growth and scientific advancement, H3 Biomedicine Inc. (H3), a biopharmaceutical company specializing in the discovery and development of oncology treatments, announced today that it has completed an expansion of its headquarters and laboratory facilities in Cambridge, Massachusetts. The increase more than doubles the company's original space to approximately 48,000 square feet, including new...

2012-11-19 08:29:16

WOODCLIFF LAKE, N.J., Nov. 19, 2012 /PRNewswire/ -- In conjunction with Eisai Co., Ltd., the Eisai USA Foundation, the charitable arm of Eisai Inc., announced today that it will be making a donation of $100,000 to the Hurricane Sandy New Jersey Relief Fund as well as a $50,000 donation to the American Red Cross in an effort to help provide relief to the many areas damaged by Hurricane Sandy. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) "The devastation caused by Hurricane...

2012-11-12 08:28:33

EXTON, Pa., Nov. 12, 2012 /PRNewswire/ -- Morphotek(® )Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to its investigational cancer drug, amatuximab (MORAb-009) for the treatment of malignant pleural mesothelioma, the most common form of mesothelioma, which accounts for around 2,500 cases a year in the United States. This disease affects the pleura, which is the thin balloon shaped lining of...

2012-11-08 08:35:07

WOODCLIFF LAKE, N.J., Nov. 8, 2012 /PRNewswire/ -- With approximately two million people in the United States living with epilepsy, including a severe and rare form called Lennox-Gastaut syndrome (LGS), many more may be struggling with the demands of caring for a loved one with this condition - a task that may require around-the-clock attention and support. In recognition of November as Epilepsy Awareness Month and the inaugural LGS Awareness Day on November 1, of which Eisai is a...

2012-10-25 09:20:04

Tokyo, Oct 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has signed a global agreement with Brazil's Fundacao Oswaldo Cruz ("Fiocruz") aimed at collaborations to develop new medicines and vaccines for malaria and neglected tropical diseases (NTDs).Under the global agreement, Eisai and Fiocruz will identify research development collaborations targeting Eisai compounds for indications of malaria and NTDs. For the first collaboration, it has been decided to begin studies on...